BioCentury
ARTICLE | Financial News

Regeneron's 1Q14 earnings top Street

May 9, 2014 12:03 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported 1Q14 financial results that beat the Street and reaffirmed full-year sales guidance for ophthalmic drug Eylea aflibercept. Non-GAAP diluted EPS in the quarter was $2.26, up from $1.78 in 1Q13. According to RBC Capital, the Street was expecting 1Q14 non-GAAP EPS of $2.25. Revenues in the quarter were $626 million, beating the Street's $609.5 million estimate and up 42% from $440 million in the year's prior quarter. Worldwide sales of Eylea were $577 million, including $359 million in U.S. sales. Regeneron reaffirmed 2014 U.S. net Eylea sales guidance of $1.7-$1.8 billion. ...